⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Official Title: Phase Ib/II Clinical Study of TQB3823 Tablets Combined With Abiraterone Acetate Tablets and Prednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Study ID: NCT05405439

Study Description

Brief Summary: This is a phase Ib/II clinical study to explore the safety and efficacy of TQB3823 tablets combined with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.

Detailed Description: This is a two-phase, open-label Phase Ib clinical trial. The first phase plans to enroll 6-12 patients as two cohorts to explore the safety and of TQB3823 tablets combined with abiraterone and prednisone and the recommended dose of phase II of TQB3823. Subjects involved in cohort one accepts TQB3823 treatment during cycle one and then TQB3823 combined with abiraterone and prednisone from cycle two till the disease progression. The second phase plans to enroll a total of 40-60 subjects, aiming to evaluate the safety and efficacy of TQB3823 tablets combined with abiraterone and prednisone.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: MALE

Healthy Volunteers: No

Locations

The First Hospital of Peking University, Beijing, Beijing, China

The Southwest Hospitai of Amu, Chongqing, Chongqing, China

Chongqing Cancer Hospital, Chongqing, Chongqing, China

The Second Hospital of Harbin Medical University, Lanzhou, Gansu, China

Sun Yat-Sun University Cancer Prevertion and Treatment Center, Guangzhou, Guangdong, China

Qingyuan People's Hospital, Qingyuan, Guangdong, China

The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China

Hunan Cancer Hospital, Changsha, Hunan, China

Jiangsu Province Hospital, Nanjing, Jiangsu, China

Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning, China

Shandong Cancer Hospital, Jinan, Shandong, China

Huadong Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

The First Affiliated Hospital of The Chinese People's Liberation Army Air Force Military Medical University, Xi'an, Shanxi, China

West China Hospital,Sichuan University, Chengdu, Sichuan, China

Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

Mianyang Central Hospital, Mianyang, Sichuan, China

Zigong Fourth People's Hospital, Zigong, Sichuan, China

Cancer Hospital of Tianjin Medical University, Tianjin, Tianjin, China

The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China

The First Affiliated Hospital of Wenzhou Medical Univerity, Wenzhou, Zhejiang, China

Contact Details

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: